Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | NCEH1 | Q6PIU2 | 5/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16965297 | 0.75 | NCEH1 (0.54) | TSHRNCEH1PKMNPC1RAB9A | |
| SCHEMBL29728586 | 0.75 | NCEH1 (0.54) | TSHRNCEH1PKMNPC1RAB9A | |
| SCHEMBL16965115 | 0.70 | RAB9A (0.60) | TSHRNCEH1PKMNPC1RAB9A | |
| SCHEMBL29848737 | 0.68 | NPC1 (0.42) | TSHRPKMNPC1RAB9AKDM4E | |
| SCHEMBL12426444 | 0.67 | TSHR (0.43) | ACHETSHRPKMNPC1RAB9A | |
| SCHEMBL12426450 | 0.66 | ACHE (0.60) | ACHETSHRNCEH1KDM4E | |
| SCHEMBL14626156 | 0.66 | ACHE (0.45) | ACHETSHRNCEH1RAB9AKDM4E | |
| SCHEMBL12426436 | 0.66 | ACHE (0.44) | ACHETSHRKDM4E | |
| SCHEMBL8716660 | 0.65 | KDM4E (0.43) | TSHRPKMNPC1RAB9AKDM4E | |
| SCHEMBL9332312 | 0.64 | KDM4E (0.39) | TSHRPKMNPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977354-B2 | Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents | INSA ROUEN (FR) | 2011-07-12 | — | — | US | disclosed |
| US-7977354-B2 | Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents | INSA ROUEN (FR) | 2011-07-12 | — | — | US | disclosed |
| US-20090062279-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS | INSA ROUEN (FR) | 2009-03-05 | — | — | US | disclosed |
| US-20090062279-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS | INSA ROUEN (FR) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062279-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS | NLN, SNCA, APP | ACHE 17/4885TSHR 4786/4885NCEH1 1379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.